Improving Patient Adherence and Quality of Life in Hepatocellular Carcinoma (HCC): Anticipating and Managing Treatment Related Adverse Events Associated with Emerging Combination Regimens

A continuing medical education activity sponsored by NAMCP and AAMCN.

Novel Treatment Approaches in the Management of Hepatocellular Carcinoma (HCC): What Managed Care Needs to Know About Emerging Combination Regimens is a 3-part live webinar series that will provide attendees with the latest information in the management of HCC

This is Part 2 of the series focusing on improving clinical and economic outcomes in HCC

This activity is an archive from the webinar held March 25, 2020

This activity is valid from April 1, 2020 to April 1, 2022

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Eisai and Merck & Co.

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for about 90% of cases of primary liver cancer in the US. In 2019, it was expected that liver cancer accounted for approximately 788,000 deaths globally, making it the second leading cause of cancer-related deaths worldwide. Prognosis is especially poor for those with unresectable HCC. Fortunately, new agents have recently been approved that provide new options for clinicians in the first-line setting. Additionally, targeted therapy and immunotherapy combinations have shown improved efficacy and safety in recent clinical trials. In this webinar series, attendees will learn about the latest data necessary to make appropriate formulary decisions and care for patients with HCC around these targeted and immunotherapy combination options, especially as more are approved and become available.

Upon completion of this activity, participants will be able to:

  • Identify challenges to patient adherence and quality of life in the use of targeted and immunotherapeutic agents, and their combinations, in HCC

  • Examine adverse events commonly associated with targeted therapies and immunotherapies, both alone or in combination, used in HCC treatment

  • Explore strategies to monitor and manage adverse events associated of emerging combination regimens in HCC in order to improve patient adherence and quality of life

  • Review recent clinical data around the safety of targeted agents and immunotherapies and their effect on patient quality of life

  • Assess how treatment strategies can be affected by adverse events based on patient’s individualized needs

Faculty: David Kaplan, MD
Associate Professor
Perelman School of Medicine
University of Pennsylvania


Dr. Kaplan has served on an advisory board for Exelixis. He has received grants or research support from Bayer Healthcare, Inovio Pharmaceuticals, and Gilead Sciences. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Eisai and Merck & Co.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue